Share

CLINICAL TRIAL SEARCH RESULTS

NEW SEARCH
 Number: 201401080 Principal Investigator: Romee, Rizwan
Title: A Pilot Study of Myeloablative Allogeneic or Haploidentical Stem Cell Transplantation with High Dose PT-Cy in Relapsed/Refractory AML
Description: The purpose of this research study is to look at patient's overall health status and how their disease responds to a stem cell transplant when followed with several doses of a drug called cyclophosphamide....MORE
___________________________________________________________________________________________________
 Number: 201309091 Principal Investigator: Jacoby, Meagan
Title: A Phase I Study of Vosaroxin plus Azacitidine for Patients with Myelodysplastic Syndrome
Description: The purpose of this research study is to evaluate the safety and side effects of treating MDS with a combination of two drugs, azacitidine and vosaroxin....MORE
___________________________________________________________________________________________________
 Number: 201303012 Principal Investigator: Schroeder, Mark
Title: Phase I/II Trial of Intravenous Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation
Description: This research study aims to discover the side effects and highest dose of a drug called azacitidine that can be given after a stem cell transplant to help prevent or minimize the effects of graft-versus-host disease (GVHD). We will also look at the way azacitidine might affect whether or how a pers...MORE
___________________________________________________________________________________________________
 Number: 201210102 Principal Investigator: Welch, John
Title: Genomic Predictors of Decitabine Response in AML/MDS
Description: The purpose of this research study is to identify genetic markers which will help us predict who will respond to treatment with a drug called decitabine and who will not. Typically, between 20 and 30% of patients with AML and MDS will achieve a complete response with decitabine, while the remaining...MORE
___________________________________________________________________________________________________
 Number: 201303028 Principal Investigator: Westervelt, Peter
Title: A multicenter safety study of unlicensed, investigational cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult patients
Description: This study will evaluate the safety of administration of the investigational cord blood units....MORE
___________________________________________________________________________________________________
 Number: 201102463 Principal Investigator: Fehniger, Todd
Title: KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Description: This study is investigating a newer donor selection factor, KIR genotyping, in addition to HLA testing and other donor selection factors....MORE
___________________________________________________________________________________________________
 Number: CTSU E2906 Principal Investigator: Uy, Geoffrey
Title: Phase III Randomized Trial of Clofarabine as Induction and Post- Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >= 60 Years)
Description: This trial is studying clofarabine to see how well it works compared with daunorubicin hydrochloride and cytarabine when followed by decitabine or observation in treating older patients with newly diagnosed acute myeloid leukemia....MORE
___________________________________________________________________________________________________
 Number: CTSU CIRB S1203 Principal Investigator: Uy, Geoffrey
Title: A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Description: The purpose of this study is to compare the effects, good and/or bad of three drug combinations. We want to see if the study treatments will get rid of leukemia cells and keep them from coming back to prepare a patient who may benefit from stem cell transplant....MORE
___________________________________________________________________________________________________
 Number: CALGB E1912 Principal Investigator: Bartlett, Nancy
Title: A Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
Description: The purpose of this study is to compare the effects, good and/or bad, of two different therapies that include combinations of the drugs rituximab, fludarabine, cyclophosphamide and Ibrutinib have on you and your CLL. The first three of these drugs are standard treatments for CLL. Fludarabine and cyc...MORE
___________________________________________________________________________________________________
 Number: CALGB A041202 Principal Investigator: Bartlett, Nancy
Title: A Randomized Phase III Study of Bendamustine plus Rituximab versus Ibrutinib plus Rituximab versus Ibrutinib Alone in Untreated Older Patients (= 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
Description: The purpose of this study is to compare the effects, good and/or bad, of the drug ibrutinib, either alone or in combination with the drug rituximab, with the standard treatment for this disease. The standard treatment is chemotherapy with the drug bendamustine in combination with the drug rituxima...MORE
___________________________________________________________________________________________________
 Number: CALGB 10701 Principal Investigator: Uy, Geoffrey
Title: A Phase II Study of Dasatanib (Sprycel®) (IND #73969, NSC #732517) as Primary Therapy Followed by Transplantation for Adults >/= 18 Years with Newly Diagnosed PH+ Acute Lymphoblastic Leukemia by CALGB, ECOG, and SWOG
Description: The purpose of this study is find out what effects (good and bad) an experimental drug known as dasatinib has on patients and their leukemia....MORE
___________________________________________________________________________________________________
 Number: 201406064 Principal Investigator: Wagner-Johnston, Nina
Title: A Phase 2, Single Arm Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia with 17p Deletion
Description: The purpose of this research study is to provide more information about whether giving rituximab and IDELA (an investigational drug) together can benefit patients with CLL who have a 17p deletion. All cells in the body receive signals to grow and survive, but sometimes these signals get out of contr...MORE
___________________________________________________________________________________________________
 Number: 201310115 Principal Investigator: DiPersio, John
Title: A Phase 3, Randomized, Open Label Study Investigating the Efficacy of the BiTE Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)
Description: This study will compare blinatumomab to the standard of care chemotherapy that patients would normally receive to find out which treatment works best to treat Philadelphia negative Acute Lymphoblastic Leukemia....MORE
___________________________________________________________________________________________________
 Number: 201310013 Principal Investigator: Wagner-Johnston, Nina
Title: An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0853 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia
Description: The purpose of this study is to test the safety of an experimental drug (GDC-0853, the study drug) to determine a safe and tolerated dose, how often it should be taken, how well patients with cancer can tolerate this experimental drug, and measure how your body processes the study drug at different ...MORE
___________________________________________________________________________________________________
 Number: 201309078 Principal Investigator: DiPersio, John
Title: A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE® Antibody Blinatumomab in Adult Subjects with Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia (Alcantara Study)
Description: The purpose of this research study is to see how well blinatumomab treats relapsed/refractory Philadelphia positive Acute Lymphoblastic Leukemia and whether it causes any side effects....MORE
___________________________________________________________________________________________________
 Number: 201308060 Principal Investigator: Uy, Geoffrey
Title: An open label, Phase I/IIa, dose escalation trial to investigate the maximum tolerated dose, safety, pharmacokinetics, and efficacy of volasertib in combination with decitabine in patients >65 years with acute myeloid leukemia
Description: This study will investigate how well a new drug called volasertib (BI 6727) works when used in combination with decitabine (Dacogen®) in adult patients with AML. The study will also investigate the possible side effects of the drug. ...MORE
___________________________________________________________________________________________________
 Number: 201307074 Principal Investigator: Stockerl-Goldstein, Keith
Title: A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician’s Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Description: The purpose of this research study is to find out if MLN9708 plus dexamethasone works against systemic light chain amyloidosis better than the physician’s choice chemotherapy treatment....MORE
___________________________________________________________________________________________________
 Number: 201212112 Principal Investigator: Uy, Geoffrey
Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine plus Best Supportive Care versus Best Supportive Care as Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Complete Remission
Description: The purpose of the study is to demonstrate if maintenance therapy with oral azacitidine improves overall survival (OS) compared with placebo in subjects with AML, age = 55 years, who have achieved first complete remission following chemotherapy....MORE
___________________________________________________________________________________________________
 Number: 201210068 Principal Investigator: Uy, Geoffrey
Title: Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age with Untreated High Risk (Secondary) AML
Description: This study is designed to help us learn more about the investigational study drug, CPX-351, in elderly patients who are newly diagnosed with high risk (secondary) leukemia and have not received any treatment for the disease. Through this study, we plan to learn how safe CPX-351 is and how effective...MORE
___________________________________________________________________________________________________
 Number: 201206065 Principal Investigator: Uy, Geoffrey
Title: A Phase I, open, dose escalation trial with BI 836858 in patients with refractory or relapsed acute myeloid leukemia
Description: The purpose of this research study is to identify the highest dose of the study drug BI 836858 that does not cause unacceptable side effects and to obtain information on the safety and effectiveness of BI 836858....MORE
___________________________________________________________________________________________________
 Number: 201205111 Principal Investigator: Fehniger, Todd
Title: A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients with High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)
Description: This study is being done to evaluate a drug called CNDO-109 Activated Allogeneic Natural Killer Cells and how patients with Acute Myeloid Leukemia (AML) respond when given this therapy....MORE
___________________________________________________________________________________________________
 Number: 201301154 Principal Investigator: Dehdashti, Farrokh
Title: Imaging of Patients after Infusion of Haploidentical Genetically Modified T cells: A Pilot Study of Tracking and Toxicity and a companion to the protocol: “TK008: Randomized phase III trial of haploidentical HCT with or without an add back strategy of HSV-Tk donor lymphocytes in patients with high risk acute leukemia
___________________________________________________________________________________________________
 Number: 201011766 Principal Investigator: Westervelt, Peter
Title: Tissue Acquisition for Analysis of Genetic Progression Factors in Hematologic Diseases
___________________________________________________________________________________________________
 Number: 201102097 Principal Investigator: DiPersio, John
Title: Part I of an Assessment of Allogeneic Hematopoietic Stem Cell Transplantation in Medicare Beneficiaries with Myelodysplastic Syndrome and Related Disorders
___________________________________________________________________________________________________